Pradaxa Lawyer Michael Goetz Appointed to Leadership Role in Litigation Surrounding Blood Thinner

Share Article

The Honorable David R. Herndon has selected Michael Goetz of Morgan and Morgan to a small group of attorneys assigned with spearheading the growing litigation surrounding blood thinner Pradaxa.

I have met with dozens of clients and their families injured by Pradaxa and will give a strong voice in this case to their physical and emotional suffering.

Morgan and Morgan is pleased to announce that attorney Michael Goetz, head of the firm’s mass tort section, has been assigned a leadership role in the national litigation surrounding blood thinner Pradaxa. On Sept. 27, 2012, the Honorable David R. Herndon appointed Mr. Goetz as a member of the Plaintiffs’ Steering Committee, which is responsible for coordinating and conducting pretrial discovery and acting as a spokesperson for all plaintiffs at pretrial proceedings.

“It’s an honor to be appointed and I look forward to making meaningful contributions to this important litigation,” said Michael Goetz. “I have met with dozens of clients and their families injured by Pradaxa and will give a strong voice in this case to their physical and emotional suffering.”

Approved in 2010 to reduce the risk of stroke in blood clots in patients with non-valvular atrial fibrillation, Pradaxa was touted to replace the decades-old drug Coumadin (warfarin), which required patients to undergo weekly exams and follow certain dietary restrictions. Pradaxa was introduced as the first in a new wave of drugs which required fewer doctor visits and did not call for selective eating by its users, according to an Aug. 19 USA Today article.

More than a year after the drug was introduced to the market, the FDA issued a safety communication stating that it would be looking into reports of serious bleeding events in patients taking Pradaxa. The FDA announced that it would be looking to determine whether these reports were occurring more commonly than would be expected. According to the FDA, all anticoagulants pose a risk of serious and even fatal bleeding; however, the pending Pradaxa lawsuits* are claiming that, unlike older blood thinners, Pradaxa does not have an antidote to reverse its anti-clotting effects, putting patients at risk for irreversible and potentially fatal bleeds.

More than 100 lawsuits have been filed on behalf of patients who died or suffered serious injuries, such as gastrointestinal bleeding and cerebral hemorrhaging, while taking Pradaxa. To resolve these cases more efficiently and consistently, a panel of federal judges ordered that all current and future lawsuits involving the blood thinner be consolidated to the Southern District of Illinois before the Honorable David R. Herndon, who has set an initial hearing for Oct. 3.

Pradaxa lawyer Michael Goetz and his team at Morgan and Morgan are continuing to offer a free case evaluation to patients who experienced internal bleeding while taking the blood thinner, as well as loved ones acting on their behalf. For more information, please visit today.

  • MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois

About Morgan & Morgan

Morgan & Morgan is one of the largest exclusively plaintiffs’ law firms in the country with 15 offices throughout Florida, Georgia, Mississippi, Tennessee, and New York. The firm handles cases nationally involving personal injury, medical malpractice, consumer class action, and securities fraud, as well as complex litigation against drug and medical device manufacturers. Visit Morgan & Morgan online at for a free case evaluation and information about your legal rights.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Goetz
Visit website